Compare Chipotle Mexican Grill, Inc. (CMG) vs Davita Inc (DVA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Chipotle Mexican Grill, Inc. vs Davita Inc — how do they compare? Chipotle Mexican Grill, Inc. trades at $32.41 (market cap $40.49B), while Davita Inc trades at $179.02 (market cap $11.38B). The key difference: Chipotle Mexican Grill, Inc. is far larger — about 3.6× Davita Inc's market cap, and Davita Inc is trading nearer its 52-week high, Chipotle Mexican Grill, Inc. nearer its low. Which is the better fit depends on your goals.
| CMG | DVA | |
|---|---|---|
Market Cap | $40.49B | $11.38B |
Sector | Consumer Cyclical | Health |
52-Week High | $44.04 | $240.96 |
52-Week Low | $28.17 | $103.87 |
Enterprise Value | $45.24B | $24.10B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Chipotle Mexican Grill, Inc.
Chipotle Mexican Grill is the largest fast-casual chain restaurant in the United States, with systemwide sales of $7.5 billion in 2021. The Mexican concept is entirely company-owned, with a footprint of more than 3,000 stores, heavily indexed to the United States (though the firm maintains a small presence in Canada, the U.K., France, and Germany). Chipotle sells burritos, burrito bowls, tacos, quesadillas, and beverages, with a selling proposition built around competitive prices, high-quality food sourcing, speed of service, and convenience. The company generates its revenue entirely from restaurant sales and delivery fees.
Read more on CMG →About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →
